Advanced glycation end-product protein crosslinks (AGE crosslinks) (AGE crosslinks)

Advanced glycation end-product (AGE) protein crosslinks are stable, covalent bonds formed through the non-enzymatic reaction between reducing sugars and the amino groups of proteins, a process known as the Maillard reaction (Source: PubMed, PMID: 24003053). These crosslinks primarily affect long-lived extracellular matrix proteins such as collagen and elastin, leading to progressive tissue stiffening and impaired organ function (Source: NIH, PMC3541086). The accumulation of AGEs is a hallmark of aging and is significantly accelerated in metabolic disorders like diabetes mellitus, where they contribute to microvascular and macrovascular complications (Source: StatPearls, NBK544260). Beyond structural damage, AGEs interact with the Receptor for Advanced Glycation End-products (RAGE) to trigger pro-inflammatory and pro-oxidative signaling pathways. Pharmacological interventions aim to either prevent the formation of these products using inhibitors like aminoguanidine or to actively cleave existing crosslinks using AGE breakers like alagebrium (Source: PubChem, CID 104971). Despite their clear role in disease pathology, developing safe and effective therapies remains a challenge due to the chemical stability of the crosslinks and the need for high specificity.

Other names

Advanced glycation end-productsAGEsProtein-AGE crosslinksMaillard reaction productsGlycation crosslinks

Cleavage of established alpha-diketone protein crosslinks (AGE breakers) and inhibition of the Maillard reaction sequence to prevent crosslink formation (AGE inhibitors).